Evidence map›Paper›PMID 26210384›Full record

Trial reportInternational journal of hematology2015

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.

Myeong Seok Koh, Won Seog Kim, Seok Jin Kim, Sung Yong Oh, Dok Hyun Yoon, Soon Il Lee, Junshik Hong, Moo Kon Song, Ho-Jin Shin, Jung Hye Kwon and 4 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Myeong Seok KohDepartment of Internal Medicine, Dong-A University College of Medicine, Daeshin Park road 26, Seo-gu, Pusan, 602-715, Korea.
Won Seog KimDivision of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Seok Jin KimDivision of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sung Yong OhDepartment of Internal Medicine, Dong-A University College of Medicine, Daeshin Park road 26, Seo-gu, Pusan, 602-715, Korea. drosy@dau.ac.kr.
Dok Hyun YoonDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Soon Il LeeDepartment of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
Junshik HongDepartment of Internal Medicine, Gachon Medical School, Inchon, Korea.
Moo Kon SongDepartment of Internal Medicine, Pusan National University, Pusan, Korea.
Ho-Jin ShinDepartment of Internal Medicine, Pusan National University, Pusan, Korea.
Jung Hye KwonDepartment of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
Hyo Jung KimDepartment of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
Yong Rok DoDepartment of Internal Medicine, Dongsan Medical Center, Taegu, Korea.
Cheolwon SuhDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. csuh@amc.seoul.kr.
Hyo Jin KimDepartment of Internal Medicine, Dong-A University College of Medicine, Daeshin Park road 26, Seo-gu, Pusan, 602-715, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even though local stage (Ann Arbor stage I/II) marginal zone lymphoma (MZL) is well controlled with local treatment-based therapy, no data exist on the role of additional chemotherapy after local treatment for stage I/II MZL. Patients with biopsy-confirmed Ann Arbor stage I/II MZL (n = 210) were included for analysis in this study. Of these, 180 patients (85.7 %) were stage I and 30 (14.3 %) were stage II. Most patients (n = 182, 86.7 %) were treated with a local modality including radiation therapy or surgery and 28 (13.3 %) received additional systemic chemotherapy after local treatment. The overall response rate was 98.3 % (95 % CI 96-100 %), with 187 complete responses and 20 partial responses. In the local treatment group, the mean progression-free survival (PFS) was 147.4 months (95 % CI 126.7-168.1 months) and the overall survival (OS) was 188.2 months (95 % CI 178.8-197.7 months). In the additional chemotherapy group, the mean PFS was 103.4 months (95 % CI 84.9-121.9 months) and the OS was 137.3 months (95 % CI 127.9-146.7 months). There was no difference between the two groups in OS (p = 0.836) and PFS (p = 0.695). Local stage MZL has a good clinical course and is well controlled with a local treatment modality without additional chemotherapy.

Indexed as

AdolescentAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedNeoplasm StagingSurvival RateB cell lymphomaChemotherapyLocal stageMarginal zone

Identifiers

PMID26210384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.